MADRIGAL PHARMACEUTICALS, INC. — Director's Dealing 2023

Jan 20, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK: 0001157601
Period of Report: 2023-01-17

Reporting Person: Levy Richard S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-17	Common Stock	M	12489	$105.08	Acquired	21589	Direct
2023-01-17	Common Stock	M	10000	$100.45	Acquired	31589	Direct
2023-01-17	Common Stock	S	100	$285.28	Disposed	31489	Direct
2023-01-17	Common Stock	S	400	$287.08	Disposed	31089	Direct
2023-01-17	Common Stock	S	300	$288.91	Disposed	30789	Direct
2023-01-17	Common Stock	S	1600	$290.36	Disposed	29189	Direct
2023-01-17	Common Stock	S	3325	$291.66	Disposed	25864	Direct
2023-01-17	Common Stock	S	5227	$292.68	Disposed	20637	Direct
2023-01-17	Common Stock	S	3548	$293.54	Disposed	17089	Direct
2023-01-17	Common Stock	S	5164	$294.68	Disposed	11925	Direct
2023-01-17	Common Stock	S	2325	$295.45	Disposed	9600	Direct
2023-01-17	Common Stock	S	500	$296.68	Disposed	9100	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-17	Stock Option (Right to buy)	$105.08	M	12489	Disposed	2024-06-17	Common Stock (12489)	Direct
2023-01-17	Stock Option (Right to Buy)	$100.45	M	10000	Disposed	2024-06-27	Common Stock (10000)	Direct

Footnotes

F1: All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder.

F2: All shares issued pursuant to the exercise of these options represent 12,489 shares underlying an option award of 12,489 shares. All exercised options vested June 17, 2022.

F3: All shares issued pursuant to the exercise of these options represent 10,000 shares underlying an option award of 10,000 shares. All exercised options vested June 27, 2020.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $286.99 to $287.16, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $288.73 to $289.01, inclusive.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $289.80 to $290.79, inclusive.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $291.08 to $292.07, inclusive.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $292.11 to $293.09, inclusive.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.12 to $294.11, inclusive.

F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $294.17 to $295.16, inclusive.

F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $295.26 to $296.15, inclusive.

F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $296.43 to $296.77, inclusive.